Covered recipient · General Payments record
RAMA BALARAMAN
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$15,531.08
149 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $11,430.00 | 5 |
| Food and Beverage | $3,448.29 | 140 |
| Travel and Lodging | $353.81 | 1 |
| Education | $298.98 | 3 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 2 of 3; records 51–100 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RAMA BALARAMAN
NPI 1396709424 · CMS profile ID 154127
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
OCALA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1396709424?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RAMA BALARAMAN, NPI 1396709424, CMS profile ID 154127. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396709424?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). RAMA BALARAMAN, NPI 1396709424, CMS profile ID 154127. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396709424?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- RAMA BALARAMAN, NPI 1396709424, CMS profile ID 154127, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1396709424?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
149 matching records · $15,531.08 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 149.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $0.71 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200006074 | CMS |
| JAZZ PHARMACEUTICALS INC. | $28.88 | 08/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234323879 | CMS |
| Novartis Pharmaceuticals Corporation | $20.96 | 08/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200006070 | CMS |
| Merck Sharp & Dohme LLC | $29.23 | 08/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238190362 | CMS |
| Gilead Sciences, Inc. | $11.99 | 07/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234583130 | CMS |
| TerSera Therapeutics LLC | $15.60 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244061144 | CMS |
| Eisai Inc. | $21.72 | 07/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244506577 | CMS |
| BeOne Medicines USA, Inc. | $13.42 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202911777 | CMS |
| Agios Pharmaceuticals, Inc. | $17.78 | 07/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253249666 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,010.00 | 07/18/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222865355 | CMS |
| Exelixis Inc. | $22.89 | 07/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218801819 | CMS |
| Lilly USA, LLC | $26.04 | 07/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186871223 | CMS |
| Daiichi Sankyo Inc. | $20.37 | 07/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197086685 | CMS |
| Novartis Pharmaceuticals Corporation | $18.40 | 07/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200006066 | CMS |
| Novartis Pharmaceuticals Corporation | $2.72 | 07/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200006068 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.48 | 07/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222865351 | CMS |
| Stemline Therapeutics Inc. | $25.95 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244103056 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.37 | 07/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206334675 | CMS |
| Gilead Sciences, Inc. | $580.00 | 07/02/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234352914 | CMS |
| Janssen Biotech, Inc. | $15.27 | 07/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175173968 | CMS |
| BeOne Medicines USA, Inc. | $30.73 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202911769 | CMS |
| Coherus Oncology, Inc. | $19.03 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235237366 | CMS |
| Dendreon Pharmaceuticals LLC | $34.61 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244997791 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.68 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184880145 | CMS |
| Gilead Sciences, Inc. | $23.97 | 06/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234484600 | CMS |
| Caris MPI, Inc. | $31.87 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234278244 | CMS |
| Lilly USA, LLC | $21.16 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186857339 | CMS |
| Novocure Inc. | $28.18 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251147284 | CMS |
| GENZYME CORPORATION | $16.50 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233315084 | CMS |
| Deciphera Pharmaceuticals Inc. | $18.14 | 06/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235958103 | CMS |
| Amneal Pharmaceuticals LLC | $19.02 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1220527517 | CMS |
| Janssen Biotech, Inc. | $28.44 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175174910 | CMS |
| Genmab U.S., Inc. | $41.41 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235925304 | CMS |
| SERVIER PHARMACEUTICALS LLC | $18.30 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229108982 | CMS |
| Blueprint Medicines Corporation | $18.57 | 06/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235818811 | CMS |
| Daiichi Sankyo Inc. | $22.54 | 06/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197070241 | CMS |
| Celgene Corporation | $17.87 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184880151 | CMS |
| TerSera Therapeutics LLC | $16.38 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244061142 | CMS |
| Celgene Corporation | $20.95 | 05/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184880139 | CMS |
| Merck Sharp & Dohme LLC | $22.28 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238149880 | CMS |
| Novartis Pharmaceuticals Corporation | $11.99 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200006056 | CMS |
| Alexion Pharmaceuticals, Inc. | $20.01 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202963122 | CMS |
| Alexion Pharmaceuticals, Inc. | $9.71 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202978062 | CMS |
| Alexion Pharmaceuticals, Inc. | $5,890.00 | 05/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202978230 | CMS |
| BeOne Medicines USA, Inc. | $17.54 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202911775 | CMS |
| Alexion Pharmaceuticals, Inc. | $16.77 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202943004 | CMS |
| ARRAY BIOPHARMA INC | $12.37 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230310888 | CMS |
| Janssen Biotech, Inc. | $19.12 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175175609 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.33 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212867844 | CMS |
| Gilead Sciences, Inc. | $24.04 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234483982 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,663.72 | 2 |
| PY2025 | Principal investigator | $733,990.68 | 59 |
| PY2024 | Principal investigator | $505,687.74 | 25 |
| PY2023 | Recipient | $1,082.54 | 6 |
| PY2023 | Principal investigator | $774,093.61 | 33 |
| PY2022 | Principal investigator | $1,208,600.24 | 8 |
| PY2021 | Principal investigator | $2,186,697.99 | 10 |
| PY2020 | Principal investigator | $1,227,327.22 | 12 |
| PY2019 | Principal investigator | $610,055.01 | 33 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
61 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $20,955.56 | 11/05/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER PL | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (SEZanne) | No dispute reported | 06/30/2026 | 1202523093 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,258.00 | 10/20/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190329259 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,025.00 | 10/20/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190329309 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,025.00 | 10/20/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190341591 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,228.00 | 10/20/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190341615 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,437.75 | 10/14/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932592 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,250.00 | 09/30/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327031 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,000.00 | 09/30/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327055 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 09/30/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327065 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,500.00 | 09/30/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327071 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,800.00 | 09/30/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327085 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,250.00 | 09/30/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327107 |
| Principal investigator 1 | BeOne Medicines Ltd. | $23,100.00 | 09/30/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327221 |
| Principal investigator 1 | BeOne Medicines Ltd. | $14,400.00 | 09/30/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327287 |
| Principal investigator 1 | BeOne Medicines Ltd. | $6,245.00 | 09/24/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327053 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,498.00 | 09/24/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327239 |
| Principal investigator 1 | Genmab U.S., Inc. | $24,030.00 | 08/04/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932581 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,510.00 | 07/25/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327037 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,025.00 | 07/25/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327049 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,025.00 | 07/25/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327093 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,228.00 | 07/25/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327271 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,258.00 | 07/25/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331779 |
| Principal investigator 1 | Genmab U.S., Inc. | $26,400.00 | 07/25/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932585 |
| Principal investigator 1 | Genmab U.S., Inc. | $24,030.00 | 07/25/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932588 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,025.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA UROLOGY PARTNERS LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150069 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,050.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA UROLOGY PARTNERS LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150074 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $18,900.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA UROLOGY PARTNERS LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150078 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,430.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA UROLOGY PARTNERS LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150082 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,350.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA UROLOGY PARTNERS LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150088 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,012.50 | 07/25/2025 | Non-covered Recipient Entity FLORIDA UROLOGY PARTNERS LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154944 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,350.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA UROLOGY PARTNERS LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154948 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,033.00 | 07/09/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190327285 |
| Principal investigator 1 | Genmab U.S., Inc. | $55,890.00 | 06/05/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932560 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,580.25 | 06/05/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932564 |
| Principal investigator 1 | Genmab U.S., Inc. | $12,015.00 | 06/05/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932568 |
| Principal investigator 1 | Genmab U.S., Inc. | $14,715.00 | 06/05/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932576 |
| Principal investigator 1 | Genmab U.S., Inc. | $7,039.92 | 05/28/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932556 |
| Principal investigator 1 | BeiGene, Ltd. | $3,498.00 | 05/16/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320700 |
| Principal investigator 1 | BeiGene, Ltd. | $3,498.00 | 05/16/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325646 |
| Principal investigator 1 | BeiGene, Ltd. | $8,100.00 | 05/09/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320792 |
| Principal investigator 1 | BeiGene, Ltd. | $8,912.00 | 05/09/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190322888 |
| Principal investigator 1 | BeiGene, Ltd. | $10,125.00 | 05/09/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325040 |
| Principal investigator 1 | BeiGene, Ltd. | $3,510.00 | 05/09/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325048 |
| Principal investigator 1 | BeiGene, Ltd. | $11,140.00 | 05/09/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325604 |
| Principal investigator 1 | BeiGene, Ltd. | $10,125.00 | 05/09/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325620 |
| Principal investigator 1 | BeiGene, Ltd. | $8,100.00 | 05/09/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325634 |
| Principal investigator 1 | ABBVIE INC. | $20,000.00 | 05/07/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER PL | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202483349 |
| Principal investigator 1 | BeiGene, Ltd. | $3,498.00 | 04/25/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325016 |
| Principal investigator 1 | Genmab U.S., Inc. | $17,921.68 | 04/24/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932572 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $887.50 | 04/02/2025 | Non-covered Recipient Entity Ocala Oncology Center, Pl | A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther | No dispute reported | 06/30/2026 | 1236530873 |
| Recipient | Novartis Pharmaceuticals Corporation | $1,355.30 | 04/01/2025 | Covered Recipient Physician | CLEE011A2207 | No dispute reported | 06/30/2026 | 1190292827 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $61,263.92 | 03/24/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER PL | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185550183 |
| Principal investigator 1 | Genmab U.S., Inc. | $28,300.00 | 03/20/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932552 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $157,600.00 | 03/18/2025 | Non-covered Recipient Entity Ocala Oncology Center | An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1232932637 |
| Recipient | GlaxoSmithKline, LLC. | $308.42 | 03/14/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154952 |
| Principal investigator 1 | BeiGene, Ltd. | $3,498.00 | 03/12/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190319988 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,300.00 | 02/25/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER PL | Clinical trial to assess the efficacy and safety of an alternative dosing regimen of ribociclib in breast cancer | No dispute reported | 06/30/2026 | 1190310040 |
| Principal investigator 1 | BeiGene, Ltd. | $3,498.00 | 02/21/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320018 |
| Principal investigator 1 | BeiGene, Ltd. | $3,498.00 | 02/21/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324294 |
| Principal investigator 1 | Genmab U.S., Inc. | $43,850.60 | 01/30/2025 | Non-covered Recipient Entity OCALA ONCOLOGY OCALA MAIN | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235932548 |
| Principal investigator 1 | BeiGene, Ltd. | $3,498.00 | 01/29/2025 | Non-covered Recipient Entity Ocala Oncology Center PL | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324634 |